2-(1-Hexyloxyethyl)-2-devinyl pyropheophorbide-a

2-(1-Hexyloxyethyl)-2-devinyl pyropheophorbide-a (HPPH) is a photosensitiser chemical that is used in photodynamic therapy.[1]

2-(1-Hexyloxyethyl)-2-devinyl pyropheophorbide-a
Names
Other names
Photochlor
Identifiers
3D model (JSmol)
Abbreviations HPPH
ChemSpider
UNII
  • InChI=1S/C39H48N4O4/c1-8-10-11-12-15-47-24(7)36-22(5)30-17-29-21(4)26(13-14-35(45)46)38(42-29)27-16-34(44)37-23(6)31(43-39(27)37)18-32-25(9-2)20(3)28(40-32)19-33(36)41-30/h17-19,21,24,26,40-41H,8-16H2,1-7H3,(H,45,46)/b28-19-,29-17-,30-17-,31-18-,32-18-,33-19-,38-27-/t21-,24?,26-/m0/s1 checkY
    Key: ODJVLHDVEGAIAW-NMWXTPPCSA-N checkY
  • InChI=1/C39H48N4O4/c1-8-10-11-12-15-47-24(7)36-22(5)30-17-29-21(4)26(13-14-35(45)46)38(42-29)27-16-34(44)37-23(6)31(43-39(27)37)18-32-25(9-2)20(3)28(40-32)19-33(36)41-30/h17-19,21,24,26,40-41H,8-16H2,1-7H3,(H,45,46)/b28-19-,29-17-,30-17-,31-18-,32-18-,33-19-,38-27-/t21-,24?,26-/m0/s1
    Key: ODJVLHDVEGAIAW-NMWXTPPCBI
  • CCCCCCOC(C)C1=C2C=C3C(=C(C(=CC4=NC5=C(CC(=O)C5=C4C)C6=NC(=CC(=C1C)N2)[C@H]([C@@H]6CCC(=O)O)C)N3)CC)C
Properties
C39H48N4O4
Molar mass 636.837 g·mol−1
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
☒N verify (what is checkY☒N ?)

It is being developed under the brand name Photochlor.

Clinical trials

edit

A phase I/II clinical trial started in 1997 for esophageal cancer.[2]

A phase II trial for non-small cell lung cancer is due to run from 2007 to 2011.[3]

References

edit
  1. ^ Lobel, J; MacDonald, IJ; Ciesielski, MJ; Barone, T; Potter, WR; Pollina, J; Plunkett, RJ; Fenstermaker, RA; Dougherty, TJ (2001). "2-1-hexyloxyethyl-2-devinyl pyropheophorbide-a (HPPH) in a nude rat glioma model: implications for photodynamic therapy". Lasers in Surgery and Medicine. 29 (5): 397–405. doi:10.1002/lsm.10001. PMID 11891727. S2CID 22578518.
  2. ^ Photodynamic Therapy Using HPPH in Treating Patients With Obstructive Esophageal Tumors
  3. ^ Photodynamic Therapy Using HPPH in Treating Patients With Advanced Non-Small Cell Lung Cancer That Blocks the Air Passages
edit